文献速递肝病消化道肿瘤与早癌

肝病中的表观转录组学:基本概念与治疗潜力

Epitranscriptomics in liver disease: Basic concepts and therapeutic potential.
PubMed 文献 · J Hepatol · 2020-04-21

本文综述了表观转录组学的基本概念,重点阐述m6A RNA甲基化在脂质代谢、病毒性肝炎、非酒精性脂肪性肝病、肝癌及肿瘤转移中的生物学作用,并总结了靶向m6A调节因子的现有抑制剂,探讨了调控m6A修饰作为治疗策略的潜力。

要点

  • m6A是真核细胞mRNA最丰富的内部修饰,由甲基转移酶复合物沉积、去甲基化酶擦除、结合蛋白识别。
  • m6A修饰在肝脏生理功能及多种肝病中发挥独特作用。
  • 靶向m6A调节因子的抑制剂及调控m6A修饰的治疗策略具有潜力。

核心结论

  • m6A RNA甲基化在肝脏生理功能和多种肝病中发挥重要作用,调控m6A修饰是潜在的治疗策略。

研究设计与样本

  • 本文为综述,聚焦m6A RNA甲基化在脂质代谢、病毒性肝炎、非酒精性脂肪性肝病、肝癌和肿瘤转移中的生物学作用。

主要发现

  • m6A是真核细胞mRNA最丰富的内部修饰,在胚胎发生、癌发生和神经发生等生理过程中发挥关键作用。
  • m6A由m6A甲基转移酶复合物(METTL3/14/16、WTAP、KIAA1429和RBM15/15B)沉积,由去甲基化酶(FTO和ALKBH5)擦除,并由结合蛋白(如YTHDF1/2/3、YTHDC1/2、IGF2BP1/2/3)识别。
  • 动态转录后修饰通过调控RNA输出、转录本加工、剪接和降解等过程决定靶RNA的命运。

临床怎么用

  • 调控m6A修饰可作为肝病治疗的潜在策略,现有靶向m6A调节因子的抑制剂值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of next-generation sequencing technology and the discovery of specific antibodies targeting chemically modified nucleotides have paved the way for a new era of epitranscriptomics. Cellular RNA is known to dynamically and reversibly undergo different chemical modifications after transcription, such as N6-methyladenosine (m6A), N1-methyladenosine, N6,2'-O-dimethyladenosine, 5-methylcytosine, and 5-hydroxymethylcytidine, whose identity and location comprise the field of epitranscriptomics. Dynamic post-transcriptional modifications determine the fate of target RNAs by regulating various aspects of their processing, including RNA export, transcript processing, splicing, and degradation. The most abundant internal mRNA modification in eukaryotic cells is m6A, which exhibits essential roles in physiological processes, such as embryogenesis, carcinogenesis, and neurogenesis. m6A is deposited by the m6A methyltransferase complex (composed of METTL3/14/16, WTAP, KIAA1429, and RBM15/15B), erased by demethylases (FTO and ALKBH5), and recognised by binding proteins (e.g., YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3). The liver is the largest digestive and metabolic organ, and m6A modifications play unique roles in critical physiological hepatic functions and various liver diseases. This review focuses on the biological roles of m6A RNA methylation in lipid metabolism, viral hepatitis, non-alcoholic fatty liver disease, liver cancer, and tumour metastasis. In addition, we summarise the existing inhibitors targeting m6A regulators and discuss the potential of modulating m6A modifications as a therapeutic strategy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhao Z, Meng J, Su R, et al. Epitranscriptomics in liver disease: Basic concepts and therapeutic potential. J Hepatol. 2020. PMID: 32330603. doi:10.1016/j.jhep.2020.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。